Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash-to-Debt No Debt
INSY's Cash-to-Debt is ranked higher than
96% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. INSY: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
INSY' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: No Debt Max: No Debt
Current: No Debt
Equity-to-Asset 0.76
INSY's Equity-to-Asset is ranked higher than
61% of the 709 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. INSY: 0.76 )
Ranked among companies with meaningful Equity-to-Asset only.
INSY' s Equity-to-Asset Range Over the Past 10 Years
Min: -27  Med: 0.76 Max: 1
Current: 0.76
-27
1
Interest Coverage No Debt
INSY's Interest Coverage is ranked higher than
95% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. INSY: No Debt )
Ranked among companies with meaningful Interest Coverage only.
INSY' s Interest Coverage Range Over the Past 10 Years
Min: 34.27  Med: No Debt Max: No Debt
Current: No Debt
Piotroski F-Score: 6
Altman Z-Score: 6.43
Beneish M-Score: -3.62
WACC vs ROIC
14.69%
6.94%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 3.02
INSY's Operating Margin % is ranked higher than
82% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -92.31 vs. INSY: 3.02 )
Ranked among companies with meaningful Operating Margin % only.
INSY' s Operating Margin % Range Over the Past 10 Years
Min: -324863.64  Med: -74.22 Max: 32.79
Current: 3.02
-324863.64
32.79
Net Margin % 3.13
INSY's Net Margin % is ranked higher than
80% of the 737 Companies
in the Global Biotechnology industry.

( Industry Median: -79.00 vs. INSY: 3.13 )
Ranked among companies with meaningful Net Margin % only.
INSY' s Net Margin % Range Over the Past 10 Years
Min: -301890.91  Med: -77.2 Max: 40.67
Current: 3.13
-301890.91
40.67
ROE % 2.92
INSY's ROE % is ranked higher than
86% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. INSY: 2.92 )
Ranked among companies with meaningful ROE % only.
INSY' s ROE % Range Over the Past 10 Years
Min: -130.7  Med: -46.69 Max: 545.67
Current: 2.92
-130.7
545.67
ROA % 2.20
INSY's ROA % is ranked higher than
88% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. INSY: 2.20 )
Ranked among companies with meaningful ROA % only.
INSY' s ROA % Range Over the Past 10 Years
Min: -118.94  Med: -54.65 Max: 67.69
Current: 2.2
-118.94
67.69
ROC (Joel Greenblatt) % 17.51
INSY's ROC (Joel Greenblatt) % is ranked higher than
94% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. INSY: 17.51 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
INSY' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -2087.93  Med: -971.57 Max: 204.03
Current: 17.51
-2087.93
204.03
3-Year Revenue Growth Rate 23.70
INSY's 3-Year Revenue Growth Rate is ranked higher than
94% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. INSY: 23.70 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
INSY' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -21.5 Max: 500
Current: 23.7
0
500
3-Year EBITDA Growth Rate -32.60
INSY's 3-Year EBITDA Growth Rate is ranked lower than
99.99% of the 534 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. INSY: -32.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
INSY' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -72.2  Med: 7.35 Max: 170.4
Current: -32.6
-72.2
170.4
3-Year EPS without NRI Growth Rate -47.70
INSY's 3-Year EPS without NRI Growth Rate is ranked lower than
99.99% of the 519 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. INSY: -47.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
INSY' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -70.3  Med: -0.4 Max: 331.8
Current: -47.7
-70.3
331.8
» INSY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

INSY Guru Trades in Q1 2016

Joel Greenblatt 1,065,310 sh (+28.27%)
Paul Tudor Jones Sold Out
John Hussman Sold Out
» More
Q2 2016

INSY Guru Trades in Q2 2016

Jim Simons 229,600 sh (New)
Joel Greenblatt 943,960 sh (-11.39%)
» More
Q3 2016

INSY Guru Trades in Q3 2016

Lee Ainslie 203,860 sh (New)
Steven Cohen 367,143 sh (New)
Paul Tudor Jones 13,398 sh (New)
Jim Simons 264,500 sh (+15.20%)
Joel Greenblatt 327,060 sh (-65.35%)
» More
Q4 2016

INSY Guru Trades in Q4 2016

Arnold Schneider 44,973 sh (New)
Paul Tudor Jones 42,405 sh (+216.50%)
Lee Ainslie 274,211 sh (+34.51%)
Steven Cohen 348,627 sh (-5.04%)
Jim Simons 241,500 sh (-8.70%)
Joel Greenblatt 207,055 sh (-36.69%)
» More
» Details

Insider Trades

Latest Guru Trades with INSY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:TGTX, NAS:ADRO, NAS:VSAR, NYSE:MYOV, NAS:JNCE, NAS:ITCI, NAS:NLNK, NAS:NDRM, OTCPK:PHMMF, NAS:AMAG, NAS:ACRS, NAS:IMMU, OTCPK:MEOBF, NAS:ESPR, NAS:BCRX, OTCPK:SXMDF, OTCPK:IPHYF, NAS:KERX, NAS:PGNX, NAS:OMER » details
Traded in other countries:NPR1.Germany,
Headquarter Location:USA
Insys Therapeutics Inc is a commercial-stage specialty pharmaceutical company that develops and commercializes supportive care products. The Company's two marketed products include Subsys and Dronabinol SG Capsule.

Insys Therapeutics is a biotechnology company that develops and commercializes innovative drugs and novel drug delivery systems. The company maintains cannabinoid formulation and manufacturing, as well as sublingual spray drug delivery technology, to develop a portfolio of differentiated, wholly owned product candidates. Insys continues to specifically target oncology healthcare providers and practices. The company's sublingual spray delivery system is sourced, manufactured, and assembled by multiple third parties across the United States and Europe.

Top Ranked Articles about Insys Therapeutics Inc

Dr. Steven James Joins Insys Therapeutics as Vice President of Medical Affairs
The Klein Law Firm Announces a Class Action Filed on Behalf of INSYS Therapeutics, Inc. Shareholders and a Lead Plaintiff Deadline of May 16, 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against INSYS Therapeutics, Inc. (INSY) & Lead Plaintiff Deadline: May 16, 2017
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in INSYS Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – INSY
INSY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of INSYS Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 16, 2017 – INSY

NEW YORK, March 28, 2017 (GLOBE NEWSWIRE) -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of investors who purchased INSYS Therapeutics, Inc. (“INSYS”) (NASDAQ:INSY) securities between February 23, 2016 and March 15, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sa/insys-therapeutics-inc-2. There is no cost or obligation to you. The complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) INSYS had overstated its 2015 net revenue; (2) INSYS had misstated its sales allowances for 2016; (3) accordingly, the Company lacked effective internal controls over financial reporting; and (4) as a result, INSYS public statements were materially false and misleading at all relevant times. If you suffered a loss in INSYS you have until May 16, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sa/insys-therapeutics-inc-2 Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.  

CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: [email protected]

Read more...
Insys Announces Saeed Motahari to Become President and Chief Executive Officer and Member of the Board of Directors Effective April 17, 2017

PHOENIX, March 27, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or "the Company") today announced that, effective April 17, 2017, Saeed Motahari, will become the Company’s President and Chief Executive Officer (“CEO”) and be appointed to the Company’s Board of Directors.
“We are excited that Saeed, a 20-year veteran of the life sciences industry, has chosen to bring his immense depth of sales and marketing, managed care, and commercial operations experience to Insys.  In particular, after a thorough and deliberate search process, management and the Board of Directors strongly believe that Saeed’s broad background and outstanding leadership skills make him the right individual to advance the Company through this critical stage of our development.  We believe Saeed can execute on the promise of this business including the anticipated commercial launch of Syndros™ and the potential products in our pipeline,” stated Steven Meyer, Chairman of the Board of Directors. “I am honored the Company’s Board of Directors has entrusted me with this opportunity.  The Company’s dual product platforms of sublingual sprays and cannabinoids have the potential to address the unmet medical needs of significant populations.  I am particularly impressed by the depth of the pipeline and excited about the possibility of addressing patient needs in critical areas like epilepsy and breakthrough cancer pain. I look forward to working with the Insys management team and Board of Directors to continue the Company’s focus on putting the needs of patients first in everything we do, while ensuring long term value for the Insys stockholders,” stated Mr. Motahari.
About Mr. Motahari
Mr. Motahari joins Insys from Purdue Pharma L.P. where he was Chief Commercial Officer since May 2014 leading a successful transformation of the commercial organization as well as contributing to the business development strategy. Prior to Purdue, from 2004 – 2014, Mr. Motahari worked at Abbott Laboratories and AbbVie, including serving as Vice President of US Specialty Brands – New Launches.   Mr. Motahari also held P&L responsibility for Specialty Franchises in the Renal, Oncology, Endocrinology, Acute Care, Virology and Neuroscience therapeutic areas. He also led various commercial organizations at Abbott Laboratories, Bristol-Myers Squibb and Hoffmann-La Roche in managed care, commercial operations, global analytics and new product development. Mr. Motahari received a BS in Biology and holds a Master’s of Business degree from Concordia University, Montreal, Canada. About Insys
Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. Insys currently markets one product, SUBSYS® (fentanyl sublingual spray) but has received approval for the marketing of SYNDROS™ (dronabinol oral solution), a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule.  Insys is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with high unmet need. SUBSYS® and SYNDROS™ are trademarks of Insys Development Company, Inc., a subsidiary of Insys Therapeutics, Inc. Forward-Looking Statements This press release contains forward-looking statements, including statements regarding (i) the expectation that Mr. Motahari’s broad background and strong leadership skills make him the right individual to shepherd the Company through this critical stage of its development and to execute on the promise of this business including the anticipated commercial launch of Syndros™ and the potential products in the Company’s pipeline, (ii) the anticipated launch of SYNDROS, (iii) the belief that the Company has the potential to benefit patients in areas of unmet medical needs and (iv) the belief that SYNDROS has distinct advantages over the current formulation of dronabinol in soft gel capsule. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward-looking statements as a result of various factors, many of which are beyond our control. For a description of these risks facing the company, please see the risk factors described in our filings with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2015 and any subsequent updates that may occur in our Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to update or revise these statements, except as may be required by law. 
Contact:
Lisa M. Wilson
212-452-2793
E: [email protected]

Read more...
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Have Losses In Excess Of $100,000 From Investment In INSYS Therapeutics, Inc. (INSY) To Contact Brower Piven Before The Lead Plaintiff Deadline

STEVENSON, Md., March 24, 2017 (GLOBE NEWSWIRE) -- The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of INSYS Therapeutics, Inc. (NASDAQ:INSY) (“INSYS” or the “Company”) securities during the period between February 23, 2016 and March 15, 2017, inclusive (the “Class Period”).  Investors who wish to become proactively involved in the litigation have until May 16, 2017 to seek appointment as lead plaintiff.
If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court.  The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action.  The lead plaintiff will be selected from among applicants claiming the largest loss from investment in INSYS securities during the Class Period.  Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.  No class has yet been certified in the above action. The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants’ failure to disclose during the Class Period that INSYS had overstated its 2015 net revenue, misstated its sales allowances for 2016, and lacked effective internal controls over financial reporting. According to the complaint, following the March 15, 2017 announcement that the Company would delay the release of its financial results for the quarter and year ended December 31, 2016 and would possibly reduce 2015 net revenue and pre-tax income by as much as $5 million, the value of INSYS shares declined significantly. If you have suffered a loss in excess of $100,000 from investment in INSYS securities purchased on or after February 23, 2016 and held through the revelation of negative information during and/or at the end of the Class Period and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, without cost or obligation to you, please visit our website at http://www.browerpiven.com/currentsecuritiescases.html.  You may also request more information by contacting Brower Piven either by email at [email protected] or by telephone at (410) 415-6616.  Brower Piven also encourages anyone with information regarding the Company’s conduct during the period in question to contact the firm, including whistleblowers, former employees, shareholders and others. Attorneys at Brower Piven have extensive experience in litigating securities and other class action cases and have been advocating for the rights of shareholders since the 1980s.  If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice.  You need take no action at this time to be a member of the class.
CONTACT:  Charles J. Piven
Brower Piven, A Professional Corporation
1925 Old Valley Road
Stevenson, Maryland 21153
Telephone: 410-415-6616
[email protected]

Read more...
DEA Schedules Insys Therapeutics’ Syndros (dronabinol oral solution) as Schedule II Drug

PHOENIX, March 23, 2017 (GLOBE NEWSWIRE) -- Insys Therapeutics, Inc. (NASDAQ:INSY) ("Insys" or the “Company") today announced that the Drug Enforcement Agency (“DEA”) has issued an interim final rule that would result in Syndros™ (dronabinol oral solution) being placed in Schedule II of the Controlled Substances Act. 
On July 1, 2016, the Food and Drug Administration (“FDA”) approved the New Drug Application for Syndros. Dr. Santosh Vetticaden, Ph.D., M.D., Interim CEO, and Chief Medical Officer, stated, “Insys is looking forward to bringing this new drug product to chemotherapy patients to help alleviate their nausea and vomiting and AIDS patients with anorexia associated weight loss, respectively.” “We look forward to interacting with the FDA to finalize the labeling and subsequent launch of Syndros in the second half of 2017,” concluded Vetticaden. Important Safety Information Syndros is a cannabinoid indicated in adults for the treatment of: Anorexia associated with weight loss in patients with AIDS, andNausea and vomiting associated with cancer chemotherapy in patients who have failed to respond adequately to conventional antiemetic treatments The use of dronabinol may cause psychiatric and cognitive effects and impair mental and/or physical abilities.
Patients with cardiac disorders may experience hypotension, hypertension, syncope or tachycardia.
May cause disulfiram-like reaction.
Weigh the potential risk versus benefits before prescribing Syndros to patients with a history of seizures, including those requiring anti-epileptic medication or other factors that lower the seizure threshold.
Assess risk for abuse or misuse in patients with a history of substance abuse or dependence, prior to prescribing Syndros and monitor for the development of associated behaviors or conditions.
Consider dose reduction or discontinuation, if worsening of symptoms while on treatment.
The safety and effectiveness of Syndros have not been established in pediatric patients. About Insys Therapeutics, Inc. Insys Therapeutics is a specialty pharmaceutical company that develops and commercializes innovative drugs and novel drug delivery systems of therapeutic molecules that improve the quality of life of patients. Using proprietary sublingual spray technology and capabilities to develop pharmaceutical cannabinoids, Insys is developing a pipeline of products intending to address unmet medical needs and the clinical shortcomings of existing commercial products. Insys currently markets one product, SUBSYS® (fentanyl sublingual spray) but has received approval for the marketing of SYNDROS™ (dronabinol oral solution), a proprietary, orally administered liquid formulation of dronabinol that Insys believes has distinct advantages over the current formulation of dronabinol in soft gel capsule. Insys is committed to developing medications for potentially treating addiction to opioids, opioid overdose, epilepsy, and other disease areas with high unmet need. SUBSYS® and SYNDROS™ are trademarks of Insys Development Company, Inc., a subsidiary of Insys Therapeutics, Inc. Forward-Looking Statements This press release contains forward-looking statements, including statements regarding (i) the anticipated scheduling and launch of SYNDROS™, (ii) the belief that the Company has the potential to benefit patients in areas of unmet medical needs and (iii) the belief that SYNDROS has distinct advantages over the current formulation of dronabinol in soft gel capsule. These forward-looking statements are based on management's expectations and assumptions as of the date of this press release, and actual results may differ materially from those in these forward-looking statements as a result of various factors, many of which are beyond our control. For a description of these risks facing the company, please see the risk factors described in our filings with the United States Securities and Exchange Commission, including those factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2015 and any subsequent updates that may occur in our Quarterly Reports on Form 10-Q. Forward-looking statements speak only as of the date of this press release, and we undertake no obligation to update or revise these statements, except as may be required by law.
Contact:
Lisa M. Wilson
212-452-2793
E: [email protected]

Read more...
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against INSYS Therapeutics, Inc. (INSY) & Lead Plaintiff Deadline: May 16, 2017

NEW YORK, March 21, 2017 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against INSYS Therapeutics, Inc. (“INSYS” or the “Company”) (NASDAQ:INSY) and certain of its officers, and is on behalf of a class consisting of all persons or entities who purchased INSYS securities between February 23, 2016 and March 15, 2017, both dates inclusive (the “Class Period”). Investors are encouraged to learn more about this case by visiting the firm’s site: http://www.bgandg.com/insy.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”). The Complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose that: (1) INSYS had overstated its 2015 net revenue; (2) INSYS had misstated its sales allowances for 2016; (3) as a result, INSYS lacked effective internal controls over financial reporting; and (4) consequently, the Company’s public statements were materially false and misleading at all relevant times.    On March 15, 2017, after-market hours, INSYS announced that it postponed filing its financial results for the quarter and year ended December 31, 2016. INSYS told investors that “[t]he Audit Committee of the Company’s Board of Directors has been conducting an independent review of the Company’s processes related to estimation of, and increases to, certain sales allowances recorded during 2016, with a potential reduction of 2015 net revenue and pre-tax income not expected to exceed $5 million, as well as extended payment terms offered to certain customers during the third quarter of 2016.”  Following this news, INSYS stock dropped $0.49 per share, or 4.64%, to close at $10.06 on March 16, 2017. A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/insy or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. You have until May 16, 2017 to request that the Court appoint you as lead plaintiff.  Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.
Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | [email protected]


Read more...
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of INSYS Therapeutics, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of May 16, 2017 – INSY

NEW YORK, March 20, 2017 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of INSYS Therapeutics, Inc. (“INSYS”) (NASDAQ:INSY) between February 23, 2016 and March 15, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Southern District of New York. To get more information go to: http://www.zlk.com/pslra/insys-therapeutics-inc-2  or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you. The complaint alleges that throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) INSYS had overstated its 2015 net revenue; (2) INSYS had misstated its sales allowances for 2016; (3) accordingly, the Company lacked effective internal controls over financial reporting; and (4) as a result, INSYS public statements were materially false and misleading at all relevant times. If you suffered a loss in INSYS you have until May 16, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation involving financial fraud, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.  

CONTACT:   
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
30 Broad Street - 24th Floor
New York, NY 10004           
Tel: (212) 363-7500
Toll Free:  (877) 363-5972
Fax: (212) 363-7171
www.zlk.com

Read more...

Ratios

vs
industry
vs
history
PE Ratio 103.60
INSY's PE Ratio is ranked lower than
54% of the 240 Companies
in the Global Biotechnology industry.

( Industry Median: 28.38 vs. INSY: 103.60 )
Ranked among companies with meaningful PE Ratio only.
INSY' s PE Ratio Range Over the Past 10 Years
Min: 16.11  Med: 35 Max: 2102.86
Current: 103.6
16.11
2102.86
PE Ratio without NRI 103.60
INSY's PE Ratio without NRI is ranked lower than
53% of the 234 Companies
in the Global Biotechnology industry.

( Industry Median: 29.63 vs. INSY: 103.60 )
Ranked among companies with meaningful PE Ratio without NRI only.
INSY' s PE Ratio without NRI Range Over the Past 10 Years
Min: 15.91  Med: 34.73 Max: 736
Current: 103.6
15.91
736
Price-to-Owner-Earnings 30.66
INSY's Price-to-Owner-Earnings is ranked higher than
66% of the 138 Companies
in the Global Biotechnology industry.

( Industry Median: 35.58 vs. INSY: 30.66 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
INSY' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 12.43  Med: 29.49 Max: 817.78
Current: 30.66
12.43
817.78
PB Ratio 2.75
INSY's PB Ratio is ranked higher than
62% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. INSY: 2.75 )
Ranked among companies with meaningful PB Ratio only.
INSY' s PB Ratio Range Over the Past 10 Years
Min: 0.06  Med: 1.84 Max: 19.87
Current: 2.75
0.06
19.87
PS Ratio 3.17
INSY's PS Ratio is ranked higher than
81% of the 685 Companies
in the Global Biotechnology industry.

( Industry Median: 12.47 vs. INSY: 3.17 )
Ranked among companies with meaningful PS Ratio only.
INSY' s PS Ratio Range Over the Past 10 Years
Min: 1.74  Med: 2240 Max: 29890
Current: 3.17
1.74
29890
Price-to-Free-Cash-Flow 15.96
INSY's Price-to-Free-Cash-Flow is ranked higher than
66% of the 141 Companies
in the Global Biotechnology industry.

( Industry Median: 24.99 vs. INSY: 15.96 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
INSY' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 11.29  Med: 35.78 Max: 167.27
Current: 15.96
11.29
167.27
Price-to-Operating-Cash-Flow 13.07
INSY's Price-to-Operating-Cash-Flow is ranked higher than
71% of the 191 Companies
in the Global Biotechnology industry.

( Industry Median: 21.01 vs. INSY: 13.07 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
INSY' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.97  Med: 28.03 Max: 1288.75
Current: 13.07
9.97
1288.75
EV-to-EBIT 77.03
INSY's EV-to-EBIT is ranked higher than
55% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. INSY: 77.03 )
Ranked among companies with meaningful EV-to-EBIT only.
INSY' s EV-to-EBIT Range Over the Past 10 Years
Min: -130.9  Med: 0.7 Max: 96.8
Current: 77.03
-130.9
96.8
EV-to-EBITDA 41.58
INSY's EV-to-EBITDA is ranked higher than
57% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. INSY: 41.58 )
Ranked among companies with meaningful EV-to-EBITDA only.
INSY' s EV-to-EBITDA Range Over the Past 10 Years
Min: -228.4  Med: 0.7 Max: 72.1
Current: 41.58
-228.4
72.1
Current Ratio 2.94
INSY's Current Ratio is ranked lower than
61% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. INSY: 2.94 )
Ranked among companies with meaningful Current Ratio only.
INSY' s Current Ratio Range Over the Past 10 Years
Min: 0.14  Med: 5.41 Max: 318.82
Current: 2.94
0.14
318.82
Quick Ratio 2.66
INSY's Quick Ratio is ranked lower than
62% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. INSY: 2.66 )
Ranked among companies with meaningful Quick Ratio only.
INSY' s Quick Ratio Range Over the Past 10 Years
Min: 0.06  Med: 5.41 Max: 318.82
Current: 2.66
0.06
318.82
Days Inventory 439.55
INSY's Days Inventory is ranked lower than
96% of the 436 Companies
in the Global Biotechnology industry.

( Industry Median: 126.28 vs. INSY: 439.55 )
Ranked among companies with meaningful Days Inventory only.
INSY' s Days Inventory Range Over the Past 10 Years
Min: 169.77  Med: 427.32 Max: 1095
Current: 439.55
169.77
1095
Days Sales Outstanding 31.12
INSY's Days Sales Outstanding is ranked higher than
64% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 61.11 vs. INSY: 31.12 )
Ranked among companies with meaningful Days Sales Outstanding only.
INSY' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0.67  Med: 44.22 Max: 72.85
Current: 31.12
0.67
72.85

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.70
INSY's 3-Year Average Share Buyback Ratio is ranked lower than
84% of the 571 Companies
in the Global Biotechnology industry.

( Industry Median: -11.10 vs. INSY: -2.70 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
INSY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -269.6  Med: -14.1 Max: 49.5
Current: -2.7
-269.6
49.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 7.73
INSY's Price-to-Net-Cash is ranked lower than
62% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. INSY: 7.73 )
Ranked among companies with meaningful Price-to-Net-Cash only.
INSY' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 1  Med: 9.83 Max: 44.85
Current: 7.73
1
44.85
Price-to-Net-Current-Asset-Value 5.15
INSY's Price-to-Net-Current-Asset-Value is ranked higher than
59% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. INSY: 5.15 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
INSY' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.98  Med: 9.76 Max: 91.93
Current: 5.15
0.98
91.93
Price-to-Tangible-Book 2.76
INSY's Price-to-Tangible-Book is ranked higher than
69% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. INSY: 2.76 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
INSY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.92  Med: 8.39 Max: 84.45
Current: 2.76
0.92
84.45
Price-to-Intrinsic-Value-Projected-FCF 1.63
INSY's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
69% of the 159 Companies
in the Global Biotechnology industry.

( Industry Median: 3.16 vs. INSY: 1.63 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
INSY' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.45  Med: 5.75 Max: 18.99
Current: 1.63
1.45
18.99
Price-to-Graham-Number 3.57
INSY's Price-to-Graham-Number is ranked higher than
62% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 2.64 vs. INSY: 3.57 )
Ranked among companies with meaningful Price-to-Graham-Number only.
INSY' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 2.97  Med: 3.67 Max: 4.95
Current: 3.57
2.97
4.95
Earnings Yield (Greenblatt) % 1.29
INSY's Earnings Yield (Greenblatt) % is ranked higher than
85% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. INSY: 1.29 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
INSY' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1  Med: 119 Max: 2305
Current: 1.29
1
2305

More Statistics

Revenue (TTM) (Mil) $242.3
EPS (TTM) $ 0.10
Beta2.08
Short Percentage of Float45.96%
52-Week Range $8.70 - 19.96
Shares Outstanding (Mil)72.11

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 202 262 343
EPS ($) -0.05 0.33 0.96
EPS without NRI ($) -0.05 0.33 0.96
EPS Growth Rate
(Future 3Y To 5Y Estimate)
28.00%
Dividends per Share ($)
» More Articles for INSY

Headlines

Articles On GuruFocus.com
Dr. Steven James Joins Insys Therapeutics as Vice President of Medical Affairs Apr 24 2017 
The Klein Law Firm Announces a Class Action Filed on Behalf of INSYS Therapeutics, Inc. Shareholders Apr 06 2017 
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against INSY Apr 06 2017 
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in IN Mar 31 2017 
INSY SHAREHOLDER ALERT: The Law Offices of Vincent Wong Notifies Investors of INSYS Therapeutics, In Mar 28 2017 
Insys Announces Saeed Motahari to Become President and Chief Executive Officer and Member of the Bo Mar 27 2017 
SHAREHOLDER ALERT: Brower Piven Notifies Investors of Class Action Lawsuit And Encourages Those Who Mar 24 2017 
DEA Schedules Insys Therapeutics’ Syndros (dronabinol oral solution) as Schedule II Drug Mar 23 2017 
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against INS Mar 21 2017 
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of INSYS Therapeutics, Inc. of a Class A Mar 20 2017 

More From Other Websites
EQUITY ALERT: Levi & Korsinsky, LLP Reminds Shareholders It Has Filed in U.S. District Court to... Apr 24 2017
Dr. Steven James Joins Insys Therapeutics as Vice President of Medical Affairs Apr 24 2017
Better Know a Marijuana Stock: Insys Therapeutics Apr 21 2017
SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Apr 21 2017
ETFs with exposure to INSYS Therapeutics, Inc. : April 20, 2017 Apr 20 2017
INSY EQUITY ALERT: The Law Offices of Vincent Wong Reminds Investors of INSYS Therapeutics, Inc. of... Apr 19 2017
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in INSYS... Apr 14 2017
INVESTOR ALERT: Levi & Korsinsky, LLP Notifies Shareholders It Has Filed in U.S. District Court to... Apr 13 2017
One company symbolizes everything sickening about the opioid crisis Apr 13 2017
Biotech Movers Trading Positive Ahead of Market's Open Apr 11 2017
INSYS Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : INSY-US : April... Apr 11 2017
The Klein Law Firm Announces the Filing of a Class Action on Behalf of INSYS Therapeutics, Inc.... Apr 10 2017
5 Drug-Developing Marijuana Stocks You Need to Know Apr 10 2017
The Klein Law Firm Announces a Class Action Filed on Behalf of INSYS Therapeutics, Inc. Shareholders... Apr 06 2017
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Insys... Apr 06 2017
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against... Apr 06 2017
DepoMed, Opioid Makers Fall After Trump's FDA Pick Says America's Drug Addiction Is Out of Control Apr 05 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)